About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Corporate | Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations
Financial | Bpifrance grants Nanobiotix a 2M€ interest-free loan to support final development stage of lead product, NBTXR3
19 September 2016
Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
20 October 2016
Corporate | Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations
Published by
Candice Teo
on
3 October 2016
No translations available for this page
